Juventas' regenerative ischemia therapy moves forward
This article was originally published in Scrip
Executive Summary
Juventas Therapeutics' lead candidate JVS-100, a regenerative therapy for critical limb ischemia, has met its Phase II primary endpoints for safety and shown some hints of efficacy, the private US firm announced at the American Heart Association meeting in Chicago this week.